Page last updated: 2024-08-18

quinuclidines and Cancer of Prostate

quinuclidines has been researched along with Cancer of Prostate in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahlering, TE; Liss, MA; Morales, B; Skarecky, D	1
Ahn, H; Choi, SK; Choo, MS; Huh, KO; Kim, J; Lee, SM; Park, S; Shim, M; Song, C	1
Ali, D; Andersson, PO; Andrén, O; Bykov, VJ; Cherif, H; Juliusson, G; Lehmann, S; Moshfegh, A; Paul, C; Tidefelt, U; Uggla, B; Wiman, KG; Yachnin, J	1

Trials

2 trial(s) available for quinuclidines and Cancer of Prostate

Article	Year
Phase 1 clinical trial of Vesicare™ (solifenacin) in the treatment of urinary incontinence after radical prostatectomy. Journal of endourology, 2014, Volume: 28, Issue:10 Topics: Aged; Humans; Male; Middle Aged; Muscarinic Antagonists; Pilot Projects; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Quinuclidines; Robotic Surgical Procedures; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Incontinence	2014
The therapeutic effect of solifenacin succinate on the recovery from voiding dysfunction after radical prostatectomy in men with clinically localized prostate cancer: a prospective, randomized, controlled study. Urology, 2015, Volume: 85, Issue:5 Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Drug Therapy, Combination; Humans; Male; Midodrine; Muscarinic Antagonists; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Quinuclidines; Recovery of Function; Single-Blind Method; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Incontinence	2015

Article

Year

Phase 1 clinical trial of Vesicare™ (solifenacin) in the treatment of urinary incontinence after radical prostatectomy.

Journal of endourology, 2014, Volume: 28, Issue:10

Topics: Aged; Humans; Male; Middle Aged; Muscarinic Antagonists; Pilot Projects; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Quinuclidines; Robotic Surgical Procedures; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Incontinence

2014

The therapeutic effect of solifenacin succinate on the recovery from voiding dysfunction after radical prostatectomy in men with clinically localized prostate cancer: a prospective, randomized, controlled study.

Urology, 2015, Volume: 85, Issue:5

Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Drug Therapy, Combination; Humans; Male; Midodrine; Muscarinic Antagonists; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Quinuclidines; Recovery of Function; Single-Blind Method; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Incontinence

2015

Other Studies

1 other study(ies) available for quinuclidines and Cancer of Prostate

Article	Year
Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-10, Volume: 30, Issue:29 Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genes, p53; Hematologic Neoplasms; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Patient Safety; Pharmacogenetics; Prospective Studies; Prostatic Neoplasms; Quinuclidines; Risk Factors; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured	2012

Article

Year

Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-10, Volume: 30, Issue:29

Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genes, p53; Hematologic Neoplasms; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Patient Safety; Pharmacogenetics; Prospective Studies; Prostatic Neoplasms; Quinuclidines; Risk Factors; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured

2012